Lightbridge Corporation — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. Lightbridge is a development-stage nuclear-fuel technology company working to commercialize metallic fuel. It reported no customer revenue in the quarter or nine-month period.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $2.20m | $3.10m | $6.14m | $7.57m |
| Operating loss | $1.91m | $3.07m | $5.57m | $7.54m |
| Net loss | $1.91m | $3.06m | $5.53m | $7.46m |
| Net loss attributable to common stockholders | $2.11m | $3.25m | $6.11m | $8.01m |
| Basic and diluted loss per share | $0.31 | $0.80 | $0.92 | $2.22 |
At September 30, cash and cash equivalents were $16.1m, down from $21.5m at year-end 2020; working capital was approximately $15.4m. Nine-month operating cash use was $8.8m, investing cash use $16,000, and financing cash inflow $3.4m, primarily from common-stock issuance. The company reported no debt or credit lines. With no revenue, profit and operating margins are not meaningful.
Total liabilities were $1.1m, consisting of current liabilities; stockholders’ equity was $15.5m. Preferred stock carries 7% annual dividends paid in kind, and its stated liquidation preferences totaled approximately $7.8m. Common shares outstanding were 7.21m at quarter-end; the filing reports 8.43m common shares and equivalents, including preferred conversion shares and accrued dividends.
Changes versus prior period and notable items
- Nine-month net loss narrowed by $1.9m year over year. General and administrative expense fell $1.7m, mainly due to lower Framatome-related legal and professional fees; research and development expense rose $0.3m, principally from national-laboratory work.
- Q3 net loss narrowed by $1.2m year over year. G&A declined $1.1m, partly offset by higher R&D spending and greater grant income.
- Grant income was $0.5m for the first nine months, versus $30,000 a year earlier, and was recorded alongside related R&D costs. The company completed its INL GAIN voucher work in Q3 and began a PNNL project, expected to run through Q3 2022.
- The company paid approximately $4.2m to settle and wind down its inactive Enfission joint venture with Framatome. It also paid $695,000 to resolve a former CFO’s claim; insurers reimbursed $663,000, leaving $32,000 of costs to the company.
Outlook, risks and contingencies
Management stated that cash available at September 30 did not cover anticipated expenditures through Q3 2022 and disclosed substantial doubt about the company’s ability to continue as a going concern for the 12 months following the filing. It projected average operating cash use of approximately $1.0m per month and estimated expenditures of approximately $12m over the next 12–15 months, while warning that future R&D commitments could raise costs. Management expects continued negative cash flows and will seek equity or convertible financing, government support, grants, and strategic partners; financing may not be available on acceptable terms. The company may delay R&D or other spending, which could extend development timelines.
The filing cites an updated 15–20-year development horizon to commercialization. Management says lack of additional test-loop capacity at the Advanced Test Reactor could require an additional commercial-reactor testing stage, extending timelines and substantially increasing costs. The first small modular reactors that could use Lightbridge Fuel are expected by the company to begin operating in 2029; this is not a revenue or commercialization forecast. Risks also include technical and regulatory development, access to test facilities, funding needs, competition, government support, COVID-19-related disruption and market adoption. The filing provides no formal financial guidance.
Subsequent events: On October 29, 2021, the Series A preferred holder exchanged all its shares for 262,910 common shares, without cash payment. On November 4, the board approved accelerated vesting of 157,233 remaining RSUs for December 15, 2021. Disclosure controls were judged effective; the company reported no material change in internal control over financial reporting.
Investor facts to verify
- Cash runway assumptions, actual monthly cash burn and funding available after the stated Q3 2022 coverage period.
- Progress and costs for national-laboratory programs, including the PNNL project and the ATR test-loop capacity issue.
- Availability, timing and terms of government support, grants, partnerships or additional financing, and the resulting dilution or senior securities.
- Development milestones supporting the 15–20-year commercialization timeline and the stated potential SMR deployment timing.
- Effects of the Series A exchange and accelerated RSU vesting on fully diluted share count and future compensation expense.